Effectiveness of a 2-dose Varicella Vaccination Program in Changzhou, China, During the Transitional Period (2017-2022): a Registry-based Case-cohort Study

Overview

Journal BMC Public Health

Publisher Biomed Central

Date 2025 Jan 17

PMID 39825294

Authors

Suting Xiong

Changlei Han

Dan Wu

Xiaomeng Mi

Peipei Zhang

Han Gao

Gan Cao

Fang Yao

Cong Chen

Xufeng Lv

Affiliations

Soon will be listed here.

Abstract

Background: The benefits of improving coverage and timeliness of varicella vaccination need to be quantified in countries where varicella vaccine (VarV) has not yet been included in national immunization programs. This longitudinal study analyzed the vaccine effectiveness (VE) of the varicella vaccination program implemented in Changzhou City during the transitional period (2017-2022).

Methods: Using the Immunization Information System and National Notifiable Infectious Disease Surveillance System registry data, this retrospective case-cohort study assessed the VEs of varicella vaccination for Changzhou children born from 2016 to 2021. The subcohort was sampled using inverse probability weighting for the survival analysis design to evaluate the VEs under different dosages and cost types, eliminating confounding by age and location area. Sensitivity analysis for the exclusion part assessed the study's robustness.

Results: A total of 5,172 children (1.12%) were sampled to the subcohort for studies, including 2,299 cases. VEs significantly rose with each successive dose, reaching 82.54% and 97.91%. VEs were lower for the single-dose subgroups until 2020, with significant increases in VEs in all subgroups in 2020 and after that. Most children who did not benefit from the "1-4" Vaccination Program had lower VEs due to delayed vaccination.

Conclusion: Improving 2-dose VarV vaccine coverage and timely vaccination could enhance the immune barrier for susceptible children. During the transitional period, the "1-4" Vaccination Program of VarV positively impacted coverage and timeliness in Changzhou.

References

Leung J, Lopez A, Marin M . Changing Epidemiology of Varicella Outbreaks in the United States During the Varicella Vaccination Program, 1995-2019. J Infect Dis. 2022; 226(Suppl 4):S400-S406. PMC: 10155060. DOI: 10.1093/infdis/jiac214. View

Suh J, Choi J, Lee J, Park S . Estimation of single-dose varicella vaccine effectiveness in South Korea using mathematical modeling. Hum Vaccin Immunother. 2022; 18(5):2085468. PMC: 9621034. DOI: 10.1080/21645515.2022.2085468. View

Wang Q, Xiu S, Yang L, Huang J, Cui T, Shi N . Economic evaluation of varicella vaccination strategies in Jiangsu province, China: a decision-tree Markov model. Hum Vaccin Immunother. 2021; 17(11):4194-4202. PMC: 8828140. DOI: 10.1080/21645515.2021.1958608. View

Hu W, Cai J, Zeng D . Sample size/power calculation for stratified case-cohort design. Stat Med. 2014; 33(23):3973-85. PMC: 4159408. DOI: 10.1002/sim.6215. View

Hu P, Yang F, Li X, Wang Y, Xiao T, Li H . Effectiveness of one-dose versus two-dose varicella vaccine in children in Qingdao, China: a matched case-control study. Hum Vaccin Immunother. 2021; 17(12):5311-5315. PMC: 8903920. DOI: 10.1080/21645515.2021.1982281. View

Dorsey A . Urbanization and Infectious Disease. Am J Hum Biol. 2024; 37(1):e24197. DOI: 10.1002/ajhb.24197. View

Wang L, Yang X, Wang X, Shi P, Zhang X . Assessing vaccine effectiveness for varicella in Wuxi, China: a time-series analysis. Ann Med. 2023; 55(2):2246369. PMC: 10434998. DOI: 10.1080/07853890.2023.2246369. View

Keogh R, Mangtani P, Rodrigues L, Nguipdop Djomo P . Estimating time-varying exposure-outcome associations using case-control data: logistic and case-cohort analyses. BMC Med Res Methodol. 2016; 16:2. PMC: 4702367. DOI: 10.1186/s12874-015-0104-0. View

Yue C, Li Y, Wang Y, Liu Y, Cao L, Zhu X . The varicella vaccination pattern among children under 5 years old in selected areas in China. Oncotarget. 2017; 8(28):45612-45618. PMC: 5542212. DOI: 10.18632/oncotarget.17317. View

10.

Shi L, Lu J, Sun X, Li Z, Zhang L, Lu Y . Impact of Varicella Immunization and Public Health and Social Measures on Varicella Incidence: Insights from Surveillance Data in Shanghai, 2013-2022. Vaccines (Basel). 2023; 11(11). PMC: 10674188. DOI: 10.3390/vaccines11111674. View

11.

Mack I, Erlanger T, Lang P, Sinniger P, Perisa D, Heininger U . Dose-dependent effectiveness of acellular pertussis vaccine in infants: A population-based case-control study. Vaccine. 2019; 38(6):1444-1449. DOI: 10.1016/j.vaccine.2019.11.069. View

12.

Lee Y, Choe Y, Lee J, Kim E, Lee J, Hong K . Global varicella vaccination programs. Clin Exp Pediatr. 2022; 65(12):555-562. PMC: 9742762. DOI: 10.3345/cep.2021.01564. View

13.

Qiu L, Liu S, Zhang M, Zhong G, Peng S, Quan J . The epidemiology of varicella and effectiveness of varicella vaccine in Ganyu, China: a long-term community surveillance study. BMC Public Health. 2023; 23(1):1875. PMC: 10537126. DOI: 10.1186/s12889-023-16304-4. View

14.

Suo L, Lu L, Zhao D, Pang X . Impact of a 2-dose voluntary vaccination strategy on varicella epidemiology in Beijing, 2011-2017. Vaccine. 2020; 38(20):3690-3696. DOI: 10.1016/j.vaccine.2020.01.087. View

15.

Li Z, Yao Y, Lu X, Liu J, Huang Z, Sun X . Impact of a two-dose varicella immunization program on the incidence of varicella: a multi-year observational study in Shanghai, China. Expert Rev Vaccines. 2021; 20(9):1177-1183. DOI: 10.1080/14760584.2021.1963236. View

16.

He Y, Liu Y, Dai B, Zhao L, Lin J, Yang J . Assessing vaccination coverage, timeliness, and its temporal variations among children in a rural area in China. Hum Vaccin Immunother. 2020; 17(2):592-600. PMC: 7899668. DOI: 10.1080/21645515.2020.1772620. View

17.

Borgan O, Langholz B, Samuelsen S, Goldstein L, Pogoda J . Exposure stratified case-cohort designs. Lifetime Data Anal. 2000; 6(1):39-58. DOI: 10.1023/a:1009661900674. View

18.

Zhang H, Lai X, Patenaude B, Jit M, Fang H . Adding new childhood vaccines to China's National Immunization Program: evidence, benefits, and priorities. Lancet Public Health. 2023; 8(12):e1016-e1024. PMC: 10695764. DOI: 10.1016/S2468-2667(23)00248-7. View

19.

Shu M, Zhang D, Ma R, Yang T, Pan X . Long-term vaccine efficacy of a 2-dose varicella vaccine in China from 2011 to 2021: A retrospective observational study. Front Public Health. 2022; 10:1039537. PMC: 9679788. DOI: 10.3389/fpubh.2022.1039537. View

20.

Wang M, Li X, You M, Wang Y, Liu X, Li Z . Epidemiological Characteristics of Varicella Outbreaks - China, 2006-2022. China CDC Wkly. 2024; 5(52):1161-1166. PMC: 10757729. DOI: 10.46234/ccdcw2023.218. View